Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Shingles nerve block shows promise in preventing chronic pain

NCT ID NCT07349680

Disease control Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether an ultrasound-guided nerve block, using a steroid and local anesthetic, could better control pain from shingles and prevent postherpetic neuralgia (long-term nerve pain). 100 adults with acute shingles and moderate to severe pain were randomly assigned to receive either standard medication alone or standard medication plus the nerve block. The main goal was to see how many patients still had significant pain 90 days after the rash started.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bupivacaine and methylprednisolone
What this could lead to
If successful, this nerve block could become a standard add-on treatment to reduce severe shingles pain and lower the chance of developing long-term nerve pain.
What could go wrong
This is a single, completed study with 100 participants. The results may not apply to everyone, and nerve blocks carry risks like infection or bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

100 people

The number who actually took part.

Started

Mar 2023

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Eligibility Criteria Inclusion Criteria Age 45-65 years Diagnosed with acute thoracic herpes zoster Rash duration ≤ 14 days Moderate to severe pain, defined as NRS ≥ 4 Total sample size: 100 patients Exclusion Criteria Contraindications to thoracic paravertebral block, including: Coagulopathy Infection at the injection site Allergy to local anesthetics or steroids Immunosuppression or ongoing chemotherapy Pre-existing chronic pain in the same affected region Severe cognitive impairment or psychiatric illness preventing reliable pain assessment Pregnancy or lactation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute herpes zoster are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

herpes zoster Neuralgia, Postherpetic postherpetic neuralgia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Postherpetic neuralgia

Contacts and locations

Locations

  • Marwa Mahmoud Rady

    Asyut, 1987, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.